A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.
机构:
Royal Prince Alfred Hosp, Sydney Canc Ctr, Dept Med Oncol, Camperdown, NSW 2050, AustraliaRoyal Prince Alfred Hosp, Sydney Canc Ctr, Dept Med Oncol, Camperdown, NSW 2050, Australia